Loading
A phase 2 trial of Teniposide, Etoposide, Serplulimab and Cisplatin in Small-cell lung cancer, run by Sun Yat-sen University, now recruiting.
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study is a phase 2 interventional study registered as NCT07583511 by Sun Yat-sen University, with 90 participants planned, started 2024-02-01 and due to reach its primary completion in 2027-05-01. Interventions recorded: Teniposide, Etoposide, serplulimab, cisplatin. Conditions recorded: Small-cell Lung Cancer.
Linked to the drug Teniposide because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Teniposide, Cisplatin and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Etoposide, Cisplatin, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Cisplatin, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Etoposide, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/